New Tool: ProSource
Checkout our packaging and processing solutions finder, ProSource.
Start Your Search

Eli Lilly Asks FDA to Cancel COVID-19 Antibody Authorization

The pharmaceutical giant will use the antibody as part of a combination treatment for greater efficacy.

According to a recent Reuters article, drug giant Eli Lilly and Co. has requested that the FDA de-authorize its COVID-19 antibody, bamlanivimab. The unique request isn’t linked to safety issues, but in response to new variants of the virus that could be resistant to bamlanivimab when used alone. The government agreed, and stopped distribution of the therapy last month. Facilities that still have supply are being shipped etesevimab to pair with it for a combination treatment that’s more effective.

Together, etesevimab and bamlanivimab neutralize more COVID-19 variants than the latter can alone. Lilly noted that it will not seek authorization cancellation in any other countries, but that it prefers for it to be used as cocktail therapy. They have partnered with Amgen to meet global supply needs. 

Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Unlock Learning Here
Discover Our Content Hub
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Take Quiz
Test Your Supply Chain Smarts